New pill shows promise against deadly parasitic disease
NCT ID NCT05593666
First seen Jan 09, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tested a new oral drug, LXE408, in 101 adults and adolescents with primary visceral leishmaniasis, a serious parasitic infection. Participants received one of two LXE408 regimens or a standard intravenous treatment. The goal was to see if LXE408 could safely clear the parasite and improve symptoms by day 28.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
DrugsNeglectedD Investigational Site
Bihār, India
-
DrugsNeglectedD Investigational Site
Patna, India
Conditions
Explore the condition pages connected to this study.